MINUTES

Subject: Meeting of the Antimicrobial Resistance (AMR) One-Health Network - 5 February 2018

1. WELCOME AND ADOPTION OF THE AGENDA

The Chair opened the meeting and welcomed the participants. The agenda was adopted without modification.

2. STATE OF PLAY OF THE IMPLEMENTATION OF THE 2017 EUROPEAN AMR ACTION PLAN

The Commission services presented the background and state of play of the deliverables listed under the three pillars of the 2017 European AMR action plan i.e. (i) making the EU a best practice region: (ii) boosting research, development and innovation on AMR; (iii) shaping the global agenda on AMR.

Information was provided on the following deliverables:

(1) Under Pillar 1 "making the EU a best practice region":
   - EU guidelines on prudent use of antimicrobials in human medicine (adopted in June 2017)
   - One-Health AMR visits in Member States (started in June 2017)
   - Second JIACRA report (in July 2017)
   - Interagency opinion on AMR indicators (published in September 2017)
   - Joint Action on AMR and Healthcare Associated Infections (launched in September 2017)
   - AMR Training (BTSF) for Competent Authorities (started in November 2017)
   - European Antibiotic Awareness Day (latest event in November 2017)
   - Audits of EU legislation on AMR monitoring in food/animals (continued)
   - Fact-finding missions in Member States on prudent use of antimicrobials in animals (continued)
   - Trilogue negotiations on veterinary medicinal products and medicated feed proposals (started in January 2018)
2

(2) Under Pillar 2 "boosting research, development and innovation on AMR":
- Launch of Horizon 2020 work programme for 2018-20 (October 2017)
- Innovative Medicines Initiative (i.e. call for proposals to understand, demonstrate and quantify the value of diagnostics as tools to optimise antibiotic use and tackle antibiotic resistance (November 2017))
- InnovFin Infectious Diseases (InnovFin ID)

(3) Under Pillar 3 "shaping the global agenda on AMR ":
- Letter of intent on AMR between the FAO and the European Commission for enhancing cooperation (signed in September 2017)
- SANTE participation in Codex Alimentarius Task force on AMR (November 2017)
- SANTE collaboration with FAO on a FAO manual on practical stepwise approaches to implementing prudent antimicrobial use guidelines (initiated in January 2018)
- Joint paper of TATFAR partners on incentives for antibacterial drug development (published in October 2017)
- AMR cooperation activities with India on veterinary medicinal products (event in November 2017) and South-American countries (ongoing)
- Joint Programming Initiative on AMR (JPIAMR)
- European and Developing Countries Clinical Trial Partnership (EDCTP)
- Work with G20 and G7

3. UPDATE OF THE AMR EPIDEMIOLOGICAL SITUATION IN THE EU

EFSA and ECDC representatives gave an update on AMR epidemiological situation. Some delegations enquired about the publication of the next Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) and the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) reports. They recalled their request made to the Commission to support the Veterinary Committee on Antimicrobial Susceptibility Testing (VetCAST) and the importance of the Clinical Breakpoints. The importance of emerging AMR was also highlighted. The Commission clarified that the next JIACRA report is foreseen by end 2020 and that the ESVAC reports are published annually. As regards the VetCAST, discussions are ongoing between the EMA and the relevant SANTE unit.

4. PRESENTATION OF EU MECHANISMS TO SUPPORT MEMBER STATES TO DEVELOP AND IMPLEMENT NATIONAL ACTION PLANS AGAINST AMR

Information was provided on the following mechanisms:

- Structural Reform Support Service (SRSS)
  The Commission services presented the opportunities for technical support in the context of the SRSS. On delegations request, clarification was made on the topics that can be covered and the functioning of the support mechanism.

- Joint ECDC/SANTE One-Health visits
  An update was provided on the number of countries already visited and those planned to be visited, as well as on the reports published and to be published. The
representatives of the countries already visited acknowledged the usefulness of the exercise and encouraged the other countries to volunteer.

- **JPIAMR supporting activities**
  The goals, funding and mechanism of JPIAMR were presented. Attention was drawn to the 6th call which submission deadline for pre-proposals is March 2018.

- **Joint action on AMR and healthcare-associated infections**
  The French Coordination Team Member presented the context of the Joint Action, its objectives, organisation and work packages to foster cooperation and disseminate best practices among Member States. Attention was called upon participation of all Member States to the Advisory Committee so as to ensure uptake of the outputs from the Joint Action across the EU.

- **Use of key outcome indicators for AMR and antimicrobial consumption (AMC)**
  EFSA and ECDC presented the background and the terms of reference of the EC mandate, as well as the key outcome indicators for AMR and AMC in humans and in animals, as reported in the ECDC-EFSA-EMA Joint Opinion on Outcome Indicators on Surveillance of Antimicrobial Resistance and Use of Antimicrobials. Delegations asked for further information on the objectives of the opinion. The Commission clarified that this opinion is not intended for benchmarking of Member States but to help Member States at national level.

5. **EU strategic approach to pharmaceuticals in the environment**

The Commission services made a presentation on the issue of pharmaceuticals in the Environment in the context of the Development of a Strategic Approach. Possible options relevant to AMR were highlighted e.g. research, greener pharmaceuticals, pharmaceuticals authorisation and follow-up, Green Public Procurement, Good Manufacturing Practice, prescription practices/OTC, dialogue/information exchange between authorities, environmental monitoring, awareness-raising/training, extended producer responsibility for disposal of hazardous waste and for unused pharmaceuticals collection schemes, labelling of hazardous pharmaceuticals, livestock farming.

6. **Supporting activities in developing countries**

The Commission services presented their activities in the field of development and the context in which they operate e.g. 2030 Agenda for Sustainable Development / sustainable development goal 3 and its targets. The objectives, purpose and timelines of the activities under the EU/ACP/WHO Renewed Partnership on strengthening pharmaceutical systems were explained as well as the EuropeAid funded Pilot Project on ‘Mapping the global threat of AMR in sub Saharan countries’.

7. **Next meeting**

The next meeting should take place mid-October 2018. Delegations were invited to take the opportunity of the next meetings to present their national activities in the
field of AMR to foster mutual learning and exchange of best practices between delegations.